Merit Medical Systems (NASDAQ:MMSI) Given New $77.00 Price Target at JPMorgan Chase & Co.

Merit Medical Systems (NASDAQ:MMSI) had its price target reduced by JPMorgan Chase & Co. from $95.00 to $77.00 in a report published on Friday,Benzinga reports. They currently have an overweight rating on the medical instruments supplier’s stock.

Other research analysts also recently issued reports about the company. Wells Fargo & Company reduced their price objective on Merit Medical Systems from $78.00 to $74.00 and set an “equal weight” rating for the company in a research report on Friday. Wall Street Zen cut Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a research report on Sunday, April 5th. Canaccord Genuity Group reduced their price objective on Merit Medical Systems from $99.00 to $90.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. Robert W. Baird set a $83.00 price objective on Merit Medical Systems in a research report on Friday. Finally, Citigroup reiterated an “outperform” rating on shares of Merit Medical Systems in a research report on Monday, April 20th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $92.80.

Merit Medical Systems Stock Down 9.0%

Merit Medical Systems stock traded down $6.17 during mid-day trading on Friday, hitting $62.01. The company had a trading volume of 2,526,188 shares, compared to its average volume of 579,377. The company has a current ratio of 4.34, a quick ratio of 2.95 and a debt-to-equity ratio of 0.46. The stock’s 50 day moving average price is $70.68 and its two-hundred day moving average price is $79.78. Merit Medical Systems has a 12 month low of $61.31 and a 12 month high of $100.19. The company has a market capitalization of $3.70 billion, a PE ratio of 29.25, a price-to-earnings-growth ratio of 1.93 and a beta of 0.64.

Merit Medical Systems (NASDAQ:MMSI) last released its earnings results on Thursday, April 30th. The medical instruments supplier reported $0.94 EPS for the quarter, topping the consensus estimate of $0.84 by $0.10. Merit Medical Systems had a return on equity of 13.74% and a net margin of 9.03%.The business had revenue of $381.88 million for the quarter, compared to the consensus estimate of $377.59 million. During the same period in the previous year, the company posted $0.86 earnings per share. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. As a group, sell-side analysts anticipate that Merit Medical Systems will post 3.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Tudor Investment Corp ET AL bought a new stake in shares of Merit Medical Systems during the third quarter valued at approximately $2,913,050,000. SG Americas Securities LLC bought a new stake in shares of Merit Medical Systems during the fourth quarter valued at approximately $1,537,000. JPMorgan Chase & Co. raised its position in shares of Merit Medical Systems by 7.6% during the third quarter. JPMorgan Chase & Co. now owns 917,122 shares of the medical instruments supplier’s stock valued at $76,332,000 after buying an additional 64,920 shares during the last quarter. William Blair Investment Management LLC raised its position in shares of Merit Medical Systems by 16.8% during the third quarter. William Blair Investment Management LLC now owns 863,996 shares of the medical instruments supplier’s stock valued at $71,910,000 after buying an additional 124,396 shares during the last quarter. Finally, Thrivent Financial for Lutherans boosted its stake in Merit Medical Systems by 250.5% during the third quarter. Thrivent Financial for Lutherans now owns 750,066 shares of the medical instruments supplier’s stock valued at $62,428,000 after buying an additional 536,072 shares during the last quarter. 99.66% of the stock is currently owned by institutional investors.

Key Stories Impacting Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q1 results beat and management raised guidance — Merit reported Q1 non‑GAAP EPS of $0.94 (vs. $0.84 est.) and revenue of ~$382M (beat). The company lifted FY2026 EPS guidance to $4.01–$4.15 and reiterated revenue targets, pointing to steady segment/geographic gains and improved margins and free cash flow. Press Release
• Positive Sentiment: Operational highlights support durable cash generation — Management reported GAAP operating margin ~11.6%, non‑GAAP operating margin ~19.7%, and free cash flow up ~26%. These metrics support the company’s cash‑flow story and capital deployment (recent acquisition activity). Details
• Positive Sentiment: Acquisition expands product set — Merit closed the View Point Medical acquisition (OneMark detection/tissue marker products) for $140M (cash portion $90M), and divested the DualCap line for $28M; these moves can bolster higher‑margin therapeutic offerings. Transaction Details
• Neutral Sentiment: Earnings call / transcripts available — Call transcripts and highlights confirm beat and management commentary on organic growth, mix, and margin drivers; useful for investors who want management color. Earnings Call Transcript
• Negative Sentiment: Analysts trimmed price targets — Several firms cut PTs today (JPMorgan: $95→$77, Wells Fargo: $78→$74, Needham: $101→$90). Although ratings were maintained (overweight/equal weight/buy), the cuts reflect multiple‑compression or sector re‑rating concerns and likely contributed to selling pressure. Analyst Notes (Benzinga)
• Negative Sentiment: Market reaction driven by valuation vs. growth — Despite beats, some analysts flagged growth deceleration and applied lower sector multiples; with the stock already well off its 52‑week high, target trims can trigger headline-driven outflows. Analyst Commentary

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.